Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL975498 | 0.97 | NLRP3 (0.35) | MGLL | |
| SCHEMBL6864533 | 0.94 | MGLL (0.34) | MGLL | |
| SCHEMBL975728 | 0.92 | NLRP3 (0.33) | MGLL | |
| SCHEMBL977788 | 0.91 | TP53 (0.34) | MEN1TP53CYP1A2MAPTHPGD | |
| SCHEMBL976763 | 0.88 | GRM2 (0.33) | MEN1TP53CYP1A2MAPTHPGD | |
| SCHEMBL13715868 | 0.88 | MGLL (0.40) | MGLL | |
| SCHEMBL12922172 | 0.86 | MGLL (0.33) | MGLLMEN1TP53CYP1A2MAPT | |
| SCHEMBL12922169 | 0.86 | GRM2 (0.37) | MEN1KMT2A | |
| SCHEMBL976006 | 0.85 | TP53 (0.36) | MEN1TP53CYP1A2MAPTHPGD | |
| SCHEMBL978032 | 0.85 | TP53 (0.36) | MEN1TP53CYP1A2MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341763-B1 | N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, WITH GLYCIDYL OR ALKYLCARBONYL GROUPS AS FUNCTIONAL INITIATORS FOR CONTROLLED RADICAL POLYMERIZATION | CIBA SC HOLDING AG (CH) | 2004-06-16 | — | — | EP | claimed |
| US-7868171-B2 | N-alkoxy-4, 4-dioxy-polyalkyl-piperidines as radical polymerization initiators | CIBA SPECIALTY CHEMICALS CORP. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868171-B2 | N-alkoxy-4, 4-dioxy-polyalkyl-piperidines as radical polymerization initiators | CIBA SPECIALTY CHEMICALS CORP. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20070173570-A1 | N-alkoxy-4, 4-dioxy-polyalkyl-piperidine compounds, with glycidyl or alkylcarbonyl groups as functional initiators for controlled radical polymerization | FUSO FRANCESCO | 2007-07-26 | — | — | US | disclosed |
| US-20070173570-A1 | N-alkoxy-4, 4-dioxy-polyalkyl-piperidine compounds, with glycidyl or alkylcarbonyl groups as functional initiators for controlled radical polymerization | FUSO FRANCESCO | 2007-07-26 | — | — | US | disclosed |
| US-7235663-B2 | N-alkoxy-4,4-dioxy-polyalkyl-piperidines as radical polymerization inhibitors | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235663-B2 | N-alkoxy-4,4-dioxy-polyalkyl-piperidines as radical polymerization inhibitors | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173570-A1 | N-alkoxy-4, 4-dioxy-polyalkyl-piperidine compounds, with glycidyl or alkylcarbonyl groups as functional initiators for controlled radical polymerization | PTGER4, ALKBH3, PIGO | MGLL 2411/4885MEN1 4792/4885TP53 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.